Abstract
The authors would like to alert readers to the following update to “Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies” by Thenappan et al. Published November 20, 2020, 10(4). DOI: 10.1177/2045894020963836.
On Page 3 of the manuscript, the median (IQR) of the riociguat group at CHEST-1 baseline was wrongly stated as 1.06 (0.22–1.48) mL/mmHg. The correct values are 1.06 (0.74–1.48) mL/mmHg.
On Page 3, Table S3 is cited when referring to improvements in PAC observed in patients with CTEPH in CHEST-1 from baseline to Week 16 with riociguat versus placebo. This table should not have been cited in this location.
On Page 4, Table 2 was cited for the sentence “For every 0.5mL/mmHg increase in baseline PAC, patients had a 20% reduction in risk of death and a 15% reduction in the risk of experiencing a clinical worsening event”. Table 1 should have been cited instead.
Table S3. “PAC at baseline, Week 16, and change from baseline in CHEST-1” was not listed in the contents of the supplemental material.
The online version of this article has been updated.